Table 4.

Final mixed model including VEDO TLs, length of treatment and age of the patient at the first VEDO dose

VEDO dose
	Estimate for: logF-CPT	95% CI	P-value	No. of observations	No. of patients
Vedolizumab level (μg/mL)	−0.0156	−0.0276 to −0.0033	0.01	274	33
Length of the treatment (days)	−0.0005	−0.001–0	0.06	274	33
Age at the first vedolizumab dose	−0.0586	−0.1857–0.0691	0.38	274	33

CI confidence interval; F-CPT faecal calprotectin; TLs trough levels; VEDO vedolizumab